Anixa Biosciences, Inc. (ANIX)
| Market Cap | 91.53M +9.0% |
| Revenue (ttm) | n/a |
| Net Income | -10.31M |
| EPS | -0.32 |
| Shares Out | 33.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,632 |
| Open | 2.800 |
| Previous Close | 2.790 |
| Day's Range | 2.720 - 2.800 |
| 52-Week Range | 2.440 - 5.457 |
| Beta | 0.65 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+302.93%) |
| Earnings Date | Jun 10, 2026 |
About ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to addr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ANIX stock is "Strong Buy." The 12-month stock price target is $11.0, which is an increase of 302.93% from the latest price.
News
Anixa Biosciences’ lira-cel shows positive survival data in ovarian cancer
Anixa Biosciences (ANIX) announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the company’s follicle-stimulating hormone rec...
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Multiple patients have survived substantially beyond expected median survival, including onepatient who survived 28 months and several patients who remain alive with continued follow-up Lira-cel clini...
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
SAN JOSE, Calif., May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announ...
Anixa Biosciences awarded patent for breast cancer vaccine in Mexico
Anixa Biosciences (ANIX) announced that the Mexican Institute of Industrial Property, or IMPI, has issued Patent Number 432748, covering key aspects of the Company’s breast cancer vaccine technology. ...
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagnoses and higher triple-negative breast cancer incidence rates New patent will provide IP protection o...
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial SAN JOSE, Calif., April 22, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX...
Anixa Biosciences Transcript: Water Tower Research Insights Conference
Lean operations and strategic partnerships enable advancement of CAR-T and breast cancer vaccine programs with minimal cash burn. Promising early clinical results, especially in ovarian cancer, and a differentiated off-the-shelf vaccine approach position the company for key data releases and valuation growth in the next 12–18 months.
Anixa Biosciences Slides: Corporate presentation
Anixa Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Breast cancer vaccine met primary endpoints and generated protocol-defined immuneresponses in 74% of participants in Phase 1 clinical trial Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive ...
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trial Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive...
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
SAN JOSE, Calif., April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno...
Anixa Biosciences announces agreement with Cytovance Biologics
Anixa Biosciences (ANIX) announced that it has entered into a development and manufacturing agreement with Cytovance Biologics, a leading full-service contract development and manufacturing organizati...
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants SAN JOSE, Calif., April 1, 202...
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial status SAN JOSE, Calif., March 30, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or...
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
SAN JOSE, Calif., March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences Transcript: AGM 2026
The meeting approved all board and executive proposals, highlighted a disciplined financial strategy, and reviewed progress in clinical-stage immunotherapy programs. Both CAR T and breast cancer vaccine trials showed promising results, with commercialization discussions underway.
Anixa Biosciences Slides: FY 2026
Anixa Biosciences has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 10, 2026.
Anixa Biosciences Slides: Corporate presentation
Anixa Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Anixa Biosciences says Korean MOIP issues Notice of Allowance for new patent
Anixa Biosciences (ANIX) announced that the Korean Ministry of Intellectual Property has issued a Notice of Allowance for a new patent related to Anixa’s breast cancer vaccine technology. This patent,...
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and...
Anixa Biosciences Quarterly report: Q1 2026
Anixa Biosciences has published its Q1 2026 quarterly earnings report on March 9, 2026.
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data SAN JOSE, Calif., March 2, 2026 /PRNewswire/ -- Anixa Bioscie...
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology SAN JOSE, Calif., Feb. 23, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biot...
Anixa Biosciences Transcript: Fireside chat
Significant progress was made in both CAR-T and breast cancer vaccine programs, with strong safety and early efficacy signals in terminal ovarian cancer patients and a phase II vaccine trial set to begin within a year. Fiscal discipline and regulatory advances support a pivotal 2026.
Anixa Biosciences Press release: Fireside chat
Anixa Biosciences issued a press release on February 10, 2026, disclosing material business information to investors.